MOTS-c and SLU-PP-332 Together: What the Research Literature Covers

The short answer to the combination question

People search for whether MOTS-c and SLU-PP-332 are used together, and the honest answer from the published record is straightforward: no study in the verified literature reviewed for this page examined MOTS-c and SLU-PP-332 in combination. There is no co-administration experiment, no comparison of the pair against either compound alone, and no reported interaction data — not in cells, not in rodents, and not in humans. Everything written about the combination online is inference drawn from separate lines of research on two very different molecules.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing here describes how any compound is used, and no protocol, schedule, or comparison of regimens is offered.

What MOTS-c is

MOTS-c (mitochondrial open reading frame of the twelve S rRNA type-c) is a short peptide encoded inside mitochondrial DNA rather than in the cell nucleus. Researchers first characterised it as a 16-amino-acid microprotein encoded within the mitochondrial 12S rRNA gene, and the 2015 study reported that it targeted skeletal muscle, where it influenced the folate cycle and de novo purine biosynthesis, leading to AICAR accumulation and AMP-activated protein kinase (AMPK) activation.

Because of that mechanism, MOTS-c is usually placed in the broader family of mitochondrial-derived peptides (MDPs) — molecules produced by the mitochondrial genome that appear to act as signals to the rest of the cell. A 2023 review in Frontiers in Endocrinology summarised MOTS-c as a candidate for therapeutic exploitation across metabolic and age-related conditions, while noting that the field remains predominantly preclinical.

What researchers reported about MOTS-c

Metabolic findings

The foundational metabolic work is the 2015 Cell Metabolism paper, in which researchers reported that MOTS-c administration in mice prevented diet-induced obesity and age-dependent as well as high-fat-diet-induced insulin resistance. That paper framed MOTS-c as a regulator of metabolic homeostasis acting largely through skeletal muscle.

Later work extended the metabolic theme into disease models. A 2022 study in Pharmacological Research reported that MOTS-c relieved hyperglycemia and insulin resistance in a model of gestational diabetes mellitus. In type 1 diabetes, a streptozotocin-induced mouse study reported that MOTS-c attenuated features of diabetic cardiomyopathy. More recently, a 2025 report in Experimental & Molecular Medicine described MOTS-c preventing pancreatic islet cell senescence and delaying diabetes onset in the models used.

Skeletal muscle findings

Skeletal muscle is the tissue most consistently studied. A 2024 iScience study reported that MOTS-c directly bound and activated casein kinase 2 (CK2), proposing that interaction as a mechanism by which the peptide modulates skeletal muscle function. In a disuse model, a 2024 paper in the American Journal of Physiology reported that MOTS-c attenuated immobilization-induced skeletal muscle atrophy, with the authors attributing part of the effect to suppression of lipid infiltration into muscle. At the cell level, a 2022 study in Peptides reported that MOTS-c promoted muscle differentiation in vitro.

Other tissues and models

The MOTS-c literature has widened well beyond metabolism and muscle. A 2024 paper in Advanced Science reported that MOTS-c suppressed ovarian cancer progression in the models tested, describing a mechanism involving USP7-mediated deubiquitination of LARS1. A 2024 study in Gut reported an antiviral role for MOTS-c during hepatitis B virus infection, linked to mitochondrial remodelling. In joint tissue, a 2025 paper in Free Radical Biology & Medicine reported that MOTS-c attenuated mitochondrial dysfunction, pyroptosis, and cartilage degradation in osteoarthritis models through an Nrf2-dependent mechanism. And in a nutrition-adjacent experiment, a 2024 study in the Journal of Agricultural and Food Chemistry reported that pyrroloquinoline quinone alleviated mitochondrial damage in radiation-induced lung injury in a MOTS-c-dependent manner.

Two things are worth holding onto from that list. First, the work is overwhelmingly preclinical — cell culture and rodent models. Second, the mechanisms invoked differ by tissue (AMPK, CK2, Nrf2, mitochondrial remodelling), which is common for a signalling molecule but makes cross-model extrapolation difficult.

What SLU-PP-332 is

SLU-PP-332 is not a peptide at all. It is a synthetic small-molecule compound developed in academic medicinal-chemistry work as an agonist of the estrogen-related receptors (ERRα, ERRβ and ERRγ) — nuclear receptors involved in transcriptional control of mitochondrial biogenesis and oxidative metabolism. Because ERR signalling overlaps with pathways that are also engaged during endurance exercise, SLU-PP-332 has been discussed in popular coverage under the loose label "exercise mimetic."

Detailed outcome data for SLU-PP-332 fall outside the verified reference set used to build this page, so no doses, efficacy figures, or adverse-event findings for that compound are stated here. That restriction is deliberate: PeptideU only reports numbers and effects it can attach to a specific citation. Readers who want the primary SLU-PP-332 literature can search the compound name directly in PubMed, where the available records are preclinical.

Side by side: two different categories of molecule

Why the combination question comes up

The pairing question is not random. Several threads converge:

• Overlapping vocabulary. Both compounds are discussed in terms of mitochondria, oxidative metabolism, and skeletal muscle. When two molecules are described with the same nouns, readers reasonably assume they belong in the same conversation.
• The "exercise mimetic" framing. MOTS-c gained attention partly because the 2015 study reported effects on muscle metabolism and insulin sensitivity in mice, and SLU-PP-332 has been discussed under a similar label in media coverage. Shared framing produces shared search queries.
• Different mechanisms in the same space. One acts as a peptide signal converging on AMPK and CK2 (PMID 39559755); the other is described as a nuclear receptor agonist. Non-overlapping mechanisms in a shared pathway space is exactly the pattern that prompts people to ask about additive effects.
• Absence of information gets filled in. When no study addresses a question, forum speculation and vendor-adjacent content tend to fill the vacuum. That content is not evidence.

What a published combination study would need to contain

It is useful to know what would actually settle the question, because it clarifies how far current knowledge is from an answer. A minimally informative combination study would generally include:

1. A four-arm design — vehicle control, compound A alone, compound B alone, and both together — so that any joint effect can be separated from either single effect.
2. Defined exposure. Both agents characterised for pharmacokinetics in the same species, since a peptide and a small molecule behave very differently in absorption, distribution, and clearance.
3. Pre-specified endpoints. Mechanistic readouts such as AMPK or CK2 activation and ERR target-gene transcription, plus functional outcomes.
4. Safety monitoring. Organ histology, weight, and biochemical panels in every arm, not just the single-agent arms.
5. Interaction statistics. Formal testing for additivity, synergy, or antagonism — two compounds pushing the same pathway can produce less than the sum of their parts, not more.

None of the MOTS-c papers cited on this page were designed that way with respect to SLU-PP-332. The nearest structural analogue in the verified set is the 2024 pyrroloquinoline quinone study, in which researchers reported that a separate agent's protective effect in radiation-induced lung injury was MOTS-c-dependent — an example of how a genuine two-agent relationship is demonstrated experimentally, and how specific such demonstrations are to the agents actually tested.

Adverse Events: What Studies Report

The MOTS-c papers cited here were mechanism-and-efficacy studies in cells and animals, not safety trials, and their abstracts did not centre on adverse-event reporting. The 2015 Cell Metabolism study reported metabolic outcomes in mice; the 2024 immobilization study reported muscle and lipid outcomes; the diabetic cardiomyopathy study reported cardiac outcomes in streptozotocin-treated mice. None of these established a human tolerability profile, and the 2023 review framed MOTS-c as a candidate for therapeutic exploitation rather than an established therapy.

For the combination specifically, there is no adverse-event literature at all — not because it was studied and found uneventful, but because it has not been studied. Absence of reported harm from an experiment that was never run carries no reassurance value.

Regulatory status

Neither MOTS-c nor SLU-PP-332 is an approved drug product in the United States. Material bearing either name that circulates outside of a clinical trial is typically labelled research-use-only, which means it is not manufactured, tested, or labelled for human administration. The published work summarised above was conducted in laboratory settings under research conditions.

Key takeaways

• No study in the verified literature examined MOTS-c and SLU-PP-332 together; there is no interaction, efficacy, or safety data for the pair.
• MOTS-c is a mitochondrial-encoded 16-amino-acid peptide whose effects on muscle metabolism, insulin resistance, and obesity in mice were reported in the 2015 study, with later work extending to muscle atrophy, islet senescence, liver infection, cancer, and cartilage models.
• SLU-PP-332 is a synthetic small-molecule ERR agonist, a different class of compound from a peptide, and its primary data were not part of this page's verified reference set.
• The question is popular because both are discussed using mitochondrial and exercise-related language — which is a reason to ask, not an answer.

This page describes what researchers published. It does not recommend, endorse, or describe use of any compound, and decisions about health belong with a licensed clinician.

References

• The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Cell Metabolism, 2015)
• MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation (Frontiers in Endocrinology, 2023)
• MOTS-c modulates skeletal muscle function by directly binding and activating CK2 (iScience, 2024)
• Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration (American Journal of Physiology: Endocrinology and Metabolism, 2024)
• MOTS-c promotes muscle differentiation in vitro (Peptides, 2022)
• The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus (Pharmacological Research, 2022)
• MOTS-c Peptide Attenuated Diabetic Cardiomyopathy in STZ-Induced Type 1 Diabetic Mouse Model (Cardiovascular Drugs and Therapy, 2025)
• Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Experimental & Molecular Medicine, 2025)
• Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection (Gut, 2024)
• Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination (Advanced Science, 2024)
• MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism (Free Radical Biology & Medicine, 2025)
• Pyrroloquinoline Quinone Alleviates Mitochondria Damage in Radiation-Induced Lung Injury in a MOTS-c-Dependent Manner (Journal of Agricultural and Food Chemistry, 2024)